• Date: March 08, 2018

The Barcelona company ABAC Therapeutics has closed a Series A financing round worth 16 million euros. Specialised in discovering new antibiotics to combat multidrug-resistant bacteria, ABAC plans to allocate these funds to bring its anti-Acinetobacter baumanii programme to the clinical trial phase.

The aforementioned bacterium is a frequent cause of hospital infections, and it tops the list drawn up by the World Health Organisation of pathogens that urgently require new treatments.

Caixa Capital Risc was one of the participants in this round of financing, together with the Pontifax fund, the Global Health Science Fund, the Debiopharm Innovation Fund and the pharmaceutical company Ferrer.

More news

September 18, 2018

COMPASS extends the applications deadline for its mentoring programme on responsible innovation for SMEs

The COMPASS consultancy and mentoring scheme is open to start-ups and SMEs in the biomedicine, nanotechnology and cyber security sectors.

July 24, 2018

The Spanish biotechnology sector received almost €150 million in 2017

These is one of the conclusions reached in the latest Annual Report published by the Spanish Association of Biotech Companies (ASEBIO).

July 12, 2018

Applications open for The Scientist's Top 10 Innovations 2018

The magazine The Scientist has spent a decade publishing the latest biomedicine innovations in its annual Top 10 Innovations contest. Applications are already open for this year’s competition.